SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is closing out 2025 on a familiar biotech cocktail: fresh clinical data, a major late-stage catalyst approaching, and market activity that suggests traders are positioning for volatility. As of 12:22 UTC on Tuesday, Dec. 23, 2025, SLS stock traded around $2.64, according to market data. In the prior session, the stock closed around $2.64 after moving sharply higher on heavy volume (roughly 8.9 million shares)—a notable burst for a small-cap biotech. Investing.com So what’s behind the renewed attention? In short: SELLAS just presented updated Phase 2 AML data for SLS009 at ASH 2025,